The era of innovative Chinese medicine has arrived, and enterprises are expected to continue to benefit

【Pharmaceutical Network Market Analysis】 As a unique health resource in China, traditional Chinese medicine has great economic potential, unique scientific and technological resources, and outstanding
advantages in cultural resources and ecological resources.
For a long time, the state has attached great importance to the development of
traditional Chinese medicine.
For example, in terms of research and development, the state has continuously strengthened investment in Chinese medicine research, of which the financial allocation of Chinese medicine institutions in 2020 was 98.
19 billion yuan, an increase of 40.
83 billion yuan, or 71.
2%,
compared with 57.
36 billion yuan in 2019.
The industry said that in recent years, driven by favorable policies, the era of innovative Chinese medicine drugs has arrived, and innovative Chinese medicine enterprises are expected to continue to benefit
.
Taking Ling Pharmaceutical, an innovative Chinese medicine company, as an example, analysts said that its long-term growth is outstanding
.
For example, Yiling Pharmaceutical's two new drugs approved for marketing last year, "Kidney Nourishing Heart and Tranquility Tablets" and "Anti-depression and Annoyance Capsules", have participated in this year's national medical insurance negotiations, and if they can successfully enter the medical insurance catalogue through the negotiations, it is expected that the volume can be expected
next year.
In addition, according to the CDE website, the company has "Chai Qin Tong Shower Tablets" (Class 1.
1), "Yangzheng Deaccumulation Capsules" (Class 2.
3) to apply for IND approval, and "Qi Huang Mingmu Capsules" (Class 1.
1) to apply for NDA approval this year, and the R&D pipeline of innovative traditional Chinese medicine drugs is progressing smoothly
.
"By increasing investment in the research and development of innovative drugs, Yiling Pharmaceutical believes that the development of the company will break the market's value expectations for the traditional Chinese medicine industry in the near future, and the performance growth market is just around
the corner.
" Driven by many favorable policies, new Chinese medicine companies will usher in more opportunities
.
At the same time, the new dosage forms of traditional Chinese medicines approved for marketing in recent years have also become increasingly diversified, and the therapeutic fields have become more abundant
.
As the information shows that the new Chinese medicine drugs approved for marketing from 2010 to 2021 are mainly
granules, capsules and tablets.
After 2015, the approved dosage forms were further concentrated in granules, capsules, pills, tablets, and ointments, and injections gradually withdrew from the market
.
In terms of approved indications, the approved indications for new Chinese medicine drugs are mainly respiratory, digestive system, endocrine diseases and nervous system diseases
.
In addition, new Chinese medicine drugs are also used in gynecology, orthopedics, tumors, trauma and other fields, with diversified application scenarios
.
It is believed that with the introduction of favorable policies in the future, more innovative Chinese medicine drugs with clinical evidence-based medical value will continue to be promoted and applied, and the space is expected to be further opened, and the industry predicts that the Chinese medicine market will exceed 1 trillion yuan in 2024, and the market prospects are very impressive
.
The research and development of traditional Chinese medicine is full of vitality, and many pharmaceutical companies are competing for development opportunities
.
For example, in addition to Yiling Pharmaceutical, Tasly also accelerates the research and development
of new Chinese medicine drugs with its own profound accumulation.
It is reported that Tasly not only has a rich product pipeline, but also has made continuous progress
in the field of research and development recently.
At present, the company has developed 26 products
in the field of modern traditional Chinese medicine.
Recently, its Class 1.
1 Chinese medicine innovative drug Jiuweihua Pill has been approved for clinical trials
again.
In addition, the author also learned that the marketing registration application of Class 1.
2 innovative traditional Chinese medicine Guangqiancao total flavonoid capsules independently developed by Wuhan Optics Valley Renfu Biotechnology, a subsidiary of Renfu Pharmaceutical, has recently been approved, which can be used for the treatment of patients with dialectic dialectic of ureteral stones belonging to moist heat and heat, and the main function is to clear heat and remove dampness, diuretic and expulsion
.
According to the industry, the approval of traditional Chinese medicines has accelerated, and the number of innovative drugs approved for traditional Chinese medicines has increased
significantly in recent years.
For example, in 2020, the Drug Review Center completed 37 and 8 applications for IND and NDA of traditional Chinese medicines, and passed 28 and 4 respectively, and the number of completions and approvals was greatly increased compared with 2019, and the efficiency of review and approval was significantly improved
.
Since 2021, a total of 12 new proprietary Chinese medicines have been approved for marketing, a new number
in nearly five years.
In the five years from 2017 to 2021, a total of 20 new Chinese medicine drugs have been approved for marketing in China, and the annual number of approvals has increased from a handful to double digits, ushering in a new period of development in the research and development of
new Chinese medicines.
It is believed that in the future, driven by favorable policies, innovative Chinese medicine companies are expected to continue to benefit
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice
to anyone.